• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用诱导多能干细胞的体外基因治疗方法治疗肌肉萎缩症。

An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells.

机构信息

Department of Medicine, Lillehei Heart Institute, University of Minnesota, 312 Church Street SE, Minneapolis, Minnesota 55455, USA.

出版信息

Nat Commun. 2013;4:1549. doi: 10.1038/ncomms2550.

DOI:10.1038/ncomms2550
PMID:23462992
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3595133/
Abstract

Duchenne muscular dystrophy is a progressive and incurable neuromuscular disease caused by genetic and biochemical defects of the dystrophin-glycoprotein complex. Here we show the regenerative potential of myogenic progenitors derived from corrected dystrophic induced pluripotent stem cells generated from fibroblasts of mice lacking both dystrophin and utrophin. We correct the phenotype of dystrophic induced pluripotent stem cells using a Sleeping Beauty transposon system carrying the micro-utrophin gene, differentiate these cells into skeletal muscle progenitors and transplant them back into dystrophic mice. Engrafted muscles displayed large numbers of micro-utrophin-positive myofibers, with biochemically restored dystrophin-glycoprotein complex and improved contractile strength. The transplanted cells seed the satellite cell compartment, responded properly to injury and exhibit neuromuscular synapses. We also detect muscle engraftment after systemic delivery of these corrected progenitors. These results represent an important advance towards the future treatment of muscular dystrophies using genetically corrected autologous induced pluripotent stem cells.

摘要

杜氏肌营养不良症是一种由肌营养不良蛋白聚糖复合物的遗传和生化缺陷引起的进行性和不可治愈的神经肌肉疾病。在这里,我们展示了从缺乏肌营养不良蛋白和 utrophin 的小鼠成纤维细胞生成的经校正的肌营养不良诱导多能干细胞衍生的肌原性祖细胞的再生潜力。我们使用携带微 utrophin 基因的 Sleeping Beauty 转座子系统校正肌营养不良诱导多能干细胞的表型,将这些细胞分化为骨骼肌祖细胞并将其移植回肌营养不良小鼠体内。移植的肌肉显示出大量微 utrophin 阳性肌纤维,其肌营养不良蛋白聚糖复合物具有生物化学恢复,收缩力得到改善。移植的细胞定位于卫星细胞区室,对损伤有适当反应,并表现出神经肌肉突触。我们还在这些经校正的祖细胞全身给药后检测到肌肉移植物。这些结果代表了使用经基因校正的自体诱导多能干细胞治疗肌肉营养不良症的重要进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358d/3595133/a0a526e0762b/nihms439414f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358d/3595133/cf7a9b51f7d6/nihms439414f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358d/3595133/4ef15b079392/nihms439414f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358d/3595133/8ba8222510ea/nihms439414f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358d/3595133/10d680f17082/nihms439414f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358d/3595133/a0a526e0762b/nihms439414f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358d/3595133/cf7a9b51f7d6/nihms439414f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358d/3595133/4ef15b079392/nihms439414f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358d/3595133/8ba8222510ea/nihms439414f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358d/3595133/10d680f17082/nihms439414f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358d/3595133/a0a526e0762b/nihms439414f5.jpg

相似文献

1
An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells.利用诱导多能干细胞的体外基因治疗方法治疗肌肉萎缩症。
Nat Commun. 2013;4:1549. doi: 10.1038/ncomms2550.
2
Engraftment of human induced pluripotent stem cell-derived myogenic progenitors restores dystrophin in mice with duchenne muscular dystrophy.人诱导多能干细胞源性成肌祖细胞的植入可恢复杜氏肌营养不良症小鼠的肌营养不良蛋白。
Biol Res. 2020 May 19;53(1):22. doi: 10.1186/s40659-020-00288-1.
3
Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models.用于治疗肌肉萎缩症动物模型的非免疫原性 utrophin 基因治疗。
Nat Med. 2019 Oct;25(10):1505-1511. doi: 10.1038/s41591-019-0594-0. Epub 2019 Oct 7.
4
Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy.细胞谱系调控的肌生成用于肌营养不良蛋白替代:一种治疗肌肉营养不良的新型治疗方法。
Hum Mol Genet. 2008 Aug 15;17(16):2507-17. doi: 10.1093/hmg/ddn151. Epub 2008 May 29.
5
C-terminal-truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double-knockout mice.C 端截短的微小抗肌萎缩蛋白将肌萎缩蛋白结合蛋白和肌营养不良蛋白聚糖复合物招募到抗肌萎缩蛋白相关糖蛋白复合物中,并减轻有症状的泛素/抗肌萎缩蛋白双敲除小鼠的肌肉萎缩。
Mol Ther. 2006 Jul;14(1):79-87. doi: 10.1016/j.ymthe.2006.01.007. Epub 2006 Mar 23.
6
Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies.杜兴氏和贝克氏肌营养不良症肌肉活检中肌养蛋白水平与抗肌萎缩蛋白复合体及肌纤维再生的相关性
PLoS One. 2016 Mar 14;11(3):e0150818. doi: 10.1371/journal.pone.0150818. eCollection 2016.
7
Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping.肌营养不良症经 AAV1-U7 外显子跳跃后金毛猎犬肌肉功能恢复。
Mol Ther. 2012 Nov;20(11):2120-33. doi: 10.1038/mt.2012.181. Epub 2012 Sep 11.
8
Unacylated Ghrelin Enhances Satellite Cell Function and Relieves the Dystrophic Phenotype in Duchenne Muscular Dystrophy mdx Model.未酰化 ghrelin 增强卫星细胞功能并缓解杜氏肌营养不良症 mdx 模型的营养不良表型。
Stem Cells. 2017 Jul;35(7):1733-1746. doi: 10.1002/stem.2632. Epub 2017 May 7.
9
Expression of utrophin (dystrophin-related protein) during regeneration and maturation of skeletal muscle in canine X-linked muscular dystrophy.犬X连锁型肌营养不良症中骨骼肌再生和成熟过程中抗肌萎缩蛋白相关蛋白(肌养蛋白)的表达
Neuropathol Appl Neurobiol. 1994 Aug;20(4):359-67. doi: 10.1111/j.1365-2990.1994.tb00981.x.
10
Fetal skeletal muscle progenitors have regenerative capacity after intramuscular engraftment in dystrophin deficient mice.胎儿骨骼肌祖细胞在肌内移植到肌营养不良症缺陷小鼠后具有再生能力。
PLoS One. 2013 May 9;8(5):e63016. doi: 10.1371/journal.pone.0063016. Print 2013.

引用本文的文献

1
Galectin-3-integrin α5β1 phase separation disrupted by advanced glycation end-products impairs diabetic wound healing in rodents.晚期糖基化终产物破坏半乳糖凝集素-3-整合素α5β1相分离,损害啮齿动物的糖尿病伤口愈合。
Nat Commun. 2025 Aug 7;16(1):7287. doi: 10.1038/s41467-025-62320-w.
2
Preclinical quality, safety, and efficacy of a CGMP iPSC-derived myogenic progenitor product for the treatment of muscular dystrophies.用于治疗肌肉萎缩症的CGMP诱导多能干细胞衍生的成肌祖细胞产品的临床前质量、安全性和有效性。
Mol Ther. 2025 Jul 17. doi: 10.1016/j.ymthe.2025.07.007.
3
Effect of Notch1 signaling on muscle engraftment and maturation from pluripotent stem cells.

本文引用的文献

1
Engraftment of ES-Derived Myogenic Progenitors in a Severe Mouse Model of Muscular Dystrophy.胚胎干细胞来源的成肌祖细胞在严重肌营养不良小鼠模型中的植入。
J Stem Cell Res Ther. 2012 Jan 6;10(1). doi: 10.4172/2157-7633.S10-001.
2
Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy.遗传性矫正人诱导多能干细胞衍生祖细胞在肢带型肌营养不良症小鼠中的移植。
Sci Transl Med. 2012 Jun 27;4(140):140ra89. doi: 10.1126/scitranslmed.3003541.
3
Human ES- and iPS-derived myogenic progenitors restore DYSTROPHIN and improve contractility upon transplantation in dystrophic mice.
Notch1信号通路对多能干细胞来源的肌肉移植及成熟的影响。
Stem Cell Reports. 2025 Feb 11;20(2):102396. doi: 10.1016/j.stemcr.2024.102396. Epub 2025 Jan 30.
4
Advancing the Battle against Cystic Fibrosis: Stem Cell and Gene Therapy Insights.推进对抗囊性纤维化的战斗:干细胞与基因治疗见解
Curr Med Sci. 2024 Dec;44(6):1155-1174. doi: 10.1007/s11596-024-2936-5. Epub 2024 Dec 16.
5
Enhanced Diaphragm Muscle Function upon Satellite Cell Transplantation in Dystrophic Mice.肌卫星细胞移植改善肌营养不良小鼠的膈肌功能
Int J Mol Sci. 2024 Feb 21;25(5):2503. doi: 10.3390/ijms25052503.
6
Metabolic Changes during In Vivo Maturation of PSC-Derived Skeletal Myogenic Progenitors.PSC 来源的成肌骨骼祖细胞体内成熟过程中的代谢变化。
Cells. 2023 Dec 29;13(1):76. doi: 10.3390/cells13010076.
7
iPSCs ameliorate hypoxia-induced autophagy and atrophy in C2C12 myotubes via the AMPK/ULK1 pathway.iPSCs 通过 AMPK/ULK1 通路改善 C2C12 肌管缺氧诱导的自噬和萎缩。
Biol Res. 2023 Jun 3;56(1):29. doi: 10.1186/s40659-023-00435-4.
8
Simple and efficient differentiation of human iPSCs into contractible skeletal muscles for muscular disease modeling.高效分化人诱导多能干细胞为可收缩的骨骼肌用于肌肉疾病建模。
Sci Rep. 2023 May 25;13(1):8146. doi: 10.1038/s41598-023-34445-9.
9
Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine.遗传重编程的进展:从发育生物学到再生医学的前景。
Curr Med Chem. 2024;31(13):1646-1690. doi: 10.2174/0929867330666230503144619.
10
Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up.用于杜氏肌营养不良症的肌营养不良蛋白表达嵌合 (DEC) 细胞治疗:至少 6 个月随访的首例人体研究。
Stem Cell Rev Rep. 2023 Jul;19(5):1340-1359. doi: 10.1007/s12015-023-10530-4. Epub 2023 Mar 31.
人胚胎干细胞和诱导多能干细胞来源的成肌祖细胞在移植到肌营养不良小鼠后可恢复肌营养不良蛋白并改善收缩力。
Cell Stem Cell. 2012 May 4;10(5):610-9. doi: 10.1016/j.stem.2012.02.015.
4
Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice.β-地中海贫血症患者特异性 iPS 细胞的基因矫正及其在改善辐照 SCID 小鼠血红蛋白生成中的应用。
Cell Res. 2012 Apr;22(4):637-48. doi: 10.1038/cr.2012.23. Epub 2012 Feb 7.
5
Stem cell-mediated transfer of a human artificial chromosome ameliorates muscular dystrophy.干细胞介导的人人工染色体转移可改善肌肉萎缩症。
Sci Transl Med. 2011 Aug 17;3(96):96ra78. doi: 10.1126/scitranslmed.3002342.
6
Functional myogenic engraftment from mouse iPS cells.来自小鼠诱导多能干细胞的功能性肌源性植入。
Stem Cell Rev Rep. 2011 Nov;7(4):948-57. doi: 10.1007/s12015-011-9258-2.
7
Assessment of the myogenic stem cell compartment following transplantation of Pax3/Pax7-induced embryonic stem cell-derived progenitors.评估 Pax3/Pax7 诱导的胚胎干细胞衍生祖细胞移植后的成肌干细胞隔室。
Stem Cells. 2011 May;29(5):777-90. doi: 10.1002/stem.625.
8
Intrinsic cell memory reinforces myogenic commitment of pericyte-derived iPSCs.内源性细胞记忆增强了周细胞来源的 iPSCs 的成肌细胞特性。
J Pathol. 2011 Apr;223(5):593-603. doi: 10.1002/path.2845. Epub 2011 Feb 21.
9
Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells.在小鼠诱导多能干细胞中,12qF1 染色体上的印迹基因异常沉默。
Nature. 2010 May 13;465(7295):175-81. doi: 10.1038/nature09017. Epub 2010 Apr 25.
10
Functional substitution by TAT-utrophin in dystrophin-deficient mice.在肌营养不良蛋白缺陷小鼠中TAT-抗肌萎缩蛋白的功能替代作用
PLoS Med. 2009 May 26;6(5):e1000083. doi: 10.1371/journal.pmed.1000083.